MedTrace Logo

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

NCT06249555 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-02-13

No results posted yet for this study

Summary

The primary aim of this study is to explore the time course of response to Vedolizumab in participants with CD as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference-short form (SF), as well as other PROMIS domain SFs (fatigue, anxiety, depression, sleep disturbance, physical function, and ability to participate in social roles and activities); other PRO measures will also be assessed.

Conditions

Interventions

DRUG

Vedolizumab (VDZ)

Participants will receive VDZ as part of routine care.

DRUG

Ustekinumab (UST)

Participants will receive UST as part of routine care.

DRUG

Risankizumab (RISA)

Participants will receive RISA as part of routine care.

DRUG

Guselkumab (GUS)

Participants will receive GUS as part of routine care.

DRUG

Mirikizumab (MIR)

Participants will receive MIR as part of routine care.

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • Alimentiv Inc.

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-20
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06249555 on ClinicalTrials.gov